Plain-English translation of NCT06491056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This is an observational study following men who are receiving focal therapy for prostate cancer. Focal therapy uses techniques like extreme cold, high-intensity heat, or electrical pulses to destroy only the area of the prostate where cancer is found, rather than removing or treating the entire gland. Researchers across Asia want to track how well these treatments work and how they affect patients' lives over time.
Traditional prostate cancer treatments often affect the entire prostate gland, which can impact urinary function and sexual health. This study aims to understand whether these newer, more targeted treatments can control cancer effectively while preserving quality of life and normal body functions.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive one of several focal therapy treatments at a participating hospital in Asia—such as cryotherapy (extreme cold), HIFU (high-intensity focused ultrasound), or laser ablation. After your procedure, you would be followed over time with clinic visits, imaging scans, blood tests, and questionnaires to track how well the treatment is working and how it has affected your urinary and sexual function.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Singapore
Sponsor
Singapore General Hospital
Collaborators
National Medical Research Council (NMRC), Singapore
Enrollment target
~500 participants
Started
May 2023
Primary completion
May 2028
Age range
40 Years – 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kae Jack Tay, MBBS
Singapore General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.